Peter Friedmann to Hepatitis C
This is a "connection" page, showing publications Peter Friedmann has written about Hepatitis C.
Connection Strength
4.942
-
Bianchet E, de Gijsel D, Del Toro-Mejias LM, Stopka TJ, Hoskinson RA, Dowd P, Friedmann PD. More than Just Buying a Van: Lessons Learned from a Mobile Telehealth HCV Testing and Treatment Study. Viruses. 2024 08 30; 16(9).
Score: 0.753
-
Romo E, Bianchet E, Dowd P, Mazor KM, Stopka TJ, Friedmann PD. Syringe Access, Syringe Sharing, and Perceptions of HCV: A Qualitative Study Exploring the HCV Risk Environment in Rural Northern New England, United States. Viruses. 2024 08 27; 16(9).
Score: 0.752
-
Romo E, Stopka TJ, Jesdale BM, Wang B, Mazor KM, Friedmann PD. Association of spatial proximity to fixed-site syringe services programs with HCV serostatus and injection equipment sharing practices among people who inject drugs in rural New England, United States. Harm Reduct J. 2024 01 28; 21(1):23.
Score: 0.723
-
Romo E, Rudolph AE, Stopka TJ, Wang B, Jesdale BM, Friedmann PD. HCV serostatus and injection sharing practices among those who obtain syringes from pharmacies and directly and indirectly from syringe services programs in rural New England. Addict Sci Clin Pract. 2023 01 03; 18(1):2.
Score: 0.671
-
Kayler LK, Friedmann P. Response: effect of HCV monoinfection and HIV coinfection in kidney transplant recipients-the role of diabetes. Am J Transplant. 2015 Mar; 15(3):847-8.
Score: 0.390
-
Kayler LK, Xia Y, Friedmann P. Effect of HCV/HIV coinfection versus HCV monoinfection in kidney transplant recipients. Am J Transplant. 2015 Mar; 15(3):849-50.
Score: 0.390
-
Nolte K, Del Toro-Mejias L, Bianchet E, Tarplin S, Hoskinson R, Friedmann PD, Stopka TJ. Convenience, rapport and skill: effective rural hepatitis C treatment, qualitative findings from a mobile harm reduction-informed tele-medicine intervention in Northern New England, 2022-2024. Harm Reduct J. 2026 02 25; 23(1).
Score: 0.209
-
Tully DC, Bean DJ, Sarette J, Ngo TL, Power KA, Brook D, Cooper H, Feinberg J, Friedmann PD, Hochstatter KR, Havens JR, Babalonis S, Hurt C, Jenkins W, Korthuis PT, Miller W, Pho MT, Smith G, Stopka TJ, Tsui JI, Mixson LS, Westergaard RP, Young AM, Allen TM. Genomic surveillance uncovers regional variation in HCV transmission networks in rural United States. Nat Commun. 2025 Dec 02; 17(1):249.
Score: 0.205
-
Stopka TJ, Whitney BM, de Gijsel D, Brook DL, Friedmann PD, Taylor LE, Feinberg J, Young AM, Evon DM, Herink M, Westergaard R, Koepke R, Havens JR, Zule WA, Delaney JA, Pho MT. Medicaid Policy and Hepatitis C Treatment Among Rural People Who Use Drugs. Med Care. 2025 02 01; 63(2):77-88.
Score: 0.191
-
Tully DC, Power KA, Sarette J, Stopka TJ, Friedmann PD, Korthuis PT, Cooper H, Young AM, Seal DW, Westergaard RP, Allen TM. Validation of dried blood spots for capturing hepatitis C virus diversity for genomic surveillance. J Viral Hepat. 2024 05; 31(5):266-270.
Score: 0.181
-
Estadt AT, Miller WC, Kline D, Whitney BM, Young AM, Todd Korthuis P, Stopka TJ, Feinberg J, Zule WA, Pho MT, Friedmann PD, Westergaard RP, Eagen KV, Seaman A, Ma J, Go VF, Lancaster KE. Associations of hepatitis C virus (HCV) antibody positivity with opioid, stimulant, and polysubstance injection among people who inject drugs (PWID) in rural U.S. communities. Int J Drug Policy. 2025 07; 141:104222.
Score: 0.177
-
Xia Y, Friedmann P, Yaffe H, Phair J, Gupta A, Kayler LK. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am J Transplant. 2014 Sep; 14(9):2037-47.
Score: 0.094
-
Rhodes AG, Taxman FS, Friedmann PD, Cropsey KL. HCV in incarcerated populations: an analysis of gender and criminality on risk. J Psychoactive Drugs. 2008 Dec; 40(4):493-501.
Score: 0.063
-
Mixson LS, Zule W, Ruderman SA, Feinberg J, Stopka TJ, Sibley AL, Walters SM, Bobashev G, Cook R, Hochstatter KR, Fahey CA, Ouellet LJ, Fredericksen R, Cooper HLF, Young AM, Zibbell J, Khoury D, Friedmann PD, Miller WC, Korthuis PT, Westergaard RP, Whitney BM, Tsui JI, Crane HM, Delaney J. Prevalence and correlates of multiple injections per injection episode among people who inject drugs in rural U.S. communities. Int J Drug Policy. 2025 09; 143:104837.
Score: 0.050
-
Estadt AT, Kline D, Miller WC, Feinberg J, Hurt CB, Mixson LS, Friedmann PD, Lowe K, Tsui JI, Young AM, Cooper H, Korthuis PT, Pho MT, Jenkins W, Westergaard RP, Go VF, Brook D, Smith G, Rice DR, Lancaster KE. Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities. Harm Reduct J. 2024 11 29; 21(1):214.
Score: 0.048
-
Vassilev ZP, Strauss SM, Astone JM, Friedmann PD, Des Jarlais DC. Provision of on-site medical care to patients with hepatitis C in drug treatment units. J Health Care Poor Underserved. 2004 Nov; 15(4):663-71.
Score: 0.048